MetaCap

Edwards Lifesciences Corporation (EW)

NYSE: EWHealth CareIndustrial SpecialtiesUSD

101.85-2.03 (-1.95%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

EW stock chart

Technical analysis

Key statistics

All statistics
Market cap
$58.56B
52-week range
74.66 – 108.00
Day range
101.66 – 104.92
Volume / Avg
3.62M / 3.92M
Beta
—

52-week range

$74.66$108.00

EW stock today

Shares of Edwards Lifesciences (EW) finished lower on Nov 20 at $101.85, a drop of 1.95% or $2.03 per share, versus the S&P 500's 3.70% decline. At this level, EW sits near the top of its 52-week range of $74.66 to $108.00: 5.7% below the high, set on Nov 16, 2026 and 36.4% above the low. EW is up 19.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 19.6%.

At 59.2x trailing earnings, Edwards Lifesciences trades above the peer-group median of 22.2x. Its forward P/E of 30.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Edwards Lifesciences

Company profile

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.

Industry
Industrial Specialties
CEO
Mr. Bernard J. Zovighian
Headquarters
Irvine, CA
Employees
16,000

Financial highlights

Full financials

In fiscal 2025, Edwards Lifesciences generated $6.07 billion in revenue, up 11.5% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $1.07 billion (-74.3% year over year), for a net margin of 17.7% versus a median of 28.7% in the prior 5 years. Gross margin was 78.0% (down from 79.5%) and operating margin 20.8%.

Edwards Lifesciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$6.07B$5.44B$5.01B$4.46B$5.23B
Growth+11.55%+8.57%+12.23%-14.69%+19.29%
Net income$1.07B$4.17B$1.40B$1.52B$1.50B
EPS (diluted)$1.83$6.97$2.30$2.44$2.38

Analyst forecast

Forecast

Consensus (30 analysts)

buy

Avg. price target

$113.68+11.62%

  • Strong buy 5
  • Buy 20
  • Hold 4
  • Sell 0
  • Strong sell 1

Target range

Low $84.00High $126.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.67 vs $0.73
Surprise
-8.22%

EW news

All EW news

Edwards Lifesciences peers

Health Care sector
EW peer companies
CompanyPrice% ChgMarket capCompare
STESTERIS plc (Ireland)255.76+0.39%$24.84Bvs EW
ZBHZimmer Biomet Holdings Inc.101.10-0.36%$19.13Bvs EW
MASMasco Corporation82.60-0.23%$15.92Bvs EW
SNNSmith & Nephew SNATS Inc.29.830.00%$12.47Bvs EW
ALGNAlign Technology Inc.155.17-2.82%$10.94Bvs EW
AITApplied Industrial Technologies Inc.274.99-4.65%$10.04Bvs EW
POOLPool Corporation208.23-0.70%$7.44Bvs EW
MSAMSA Safety Incorporated170.03-3.52%$6.55Bvs EW

Indexes, lists and sector

Edwards Lifesciences stock FAQ

What is Edwards Lifesciences's stock price today?

EW last traded at $101.85 as of Nov 20, 4:00 PM EST, down 1.95% on the day. Prices are delayed at least 15 minutes.

Does Edwards Lifesciences pay a dividend?

No. Edwards Lifesciences does not currently pay a regular cash dividend.

What is EW's P/E ratio?

EW trades at a trailing P/E ratio of 59.22 and a forward P/E of 30.08, compared with a median of 22.2 for its closest peers.

Is Edwards Lifesciences in the S&P 500?

Yes. Edwards Lifesciences (EW) is a constituent of the S&P 500 index.

Who is Edwards Lifesciences's CEO?

Mr. Bernard J. Zovighian is the chief executive officer of Edwards Lifesciences Corporation, which has about 16,000 employees.

Has EW ever split its stock?

Yes. The most recent EW stock split was a 3-for-1 split on Jun 1, 2020, one of 3 splits on record.

What is the EW 52-week high?

The 52-week high for EW is $108.00 and the 52-week low is $74.66. The stock is currently 5.7% below its high.

Compare EW